{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:26:30Z","timestamp":1778567190254,"version":"3.51.4"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12969-019-0335-4","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T12:03:19Z","timestamp":1562587399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-0391","authenticated-orcid":false,"given":"Abdulkadir A.","family":"Elmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Wynne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iek L.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Eleftheriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen J.","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Brogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"issue":"3","key":"335_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/ng756","volume":"29","author":"HM Hoffman","year":"2001","unstructured":"Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and muckle-Wells syndrome. Nat Genet. 2001;29(3):301\u20135.","journal-title":"Nat Genet"},{"issue":"4","key":"335_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/art.22491","volume":"56","author":"I Aksentijevich","year":"2007","unstructured":"Aksentijevich I, Putnam CD, Remmers EF, Mueller JL, Le J, Kolodner RD, Moak Z, Chuang M, Austin F, Goldbach-Mansky R, Hoffman HM, Kastner DL. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in north American patients and a new cryopyrin model. Arthritis Rheum. 2007;56(4):1273\u201385.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"335_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/rheumatology\/ket415","volume":"53","author":"RA Russo","year":"2014","unstructured":"Russo RA, Melo-Gomes S, Lachmann HJ, Wynne K, Rajput K, Eleftheriou D, Edelsten C, Hawkins PN, Brogan PA. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-Centre, real-world experience. Rheumatology (Oxford). 2014;53(4):665\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"335_CR4","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","volume":"74","author":"NM ter Haar","year":"2015","unstructured":"ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, Cantarini L, Galeotti C, Grateau G, Hentgen V, Hofer M, Kallinich T, Kone-Paut I, Lachmann HJ, Ozdogan H, Ozen S, Russo R, Simon A, Uziel Y, Wouters C, Feldman BM, Vastert SJ, Wulffraat NM, Benseler SM, Frenkel J, Gattorno M, Kuemmerle-Deschner JB. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"335_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN. Canakinumab in CSG. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416\u201325.","journal-title":"N Engl J Med"},{"issue":"6","key":"335_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1136\/annrheumdis-2016-209686","volume":"76","author":"JB Kuemmerle-Deschner","year":"2017","unstructured":"Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, Kone-Paut I, Goldbach-Mansky R, Lachmann H, Blank N, Hoffman HM, Weissbarth-Riedel E, Hugle B, Kallinich T, Gattorno M, Gul A, Ter Haar N, Oswald M, Dedeoglu F, Cantarini L, Benseler SM. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis. 2017;76(6):942\u20137.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-019-0335-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T23:16:38Z","timestamp":1594077398000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-019-0335-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1186\/s12969-019-0335-4","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"8 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Research approval was obtained from the Joint Research and Development office (R&D Department) of GOSH. The R&D reference number was 16IR47. As per their recommendation, formal ethical approval was not required since this was a retrospective case note review with the presentation of anonymised data. Accordingly, patients and families did not have to sign a consent form to be included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (retrospective case notes review only).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Paul Brogan has received consultancy fees for Novartis, Roche, and SOBI; and institutional grants from Novartis, Roche, SOBI, and Novimmune. Helen J Lachmann has received consultancy fees for Novartis, Takeda and SOBI. Philip N Hawkins has received consultancy fees for Novartis, GSK, and Alnilam. None of the other authors had any disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}